A Breed Apart? Security Analysts and Herding Behavior

Herding behavior occurs when security analysts ignore their private opinions and issue public forecasts that mimic the earnings forecasts of others. Joining the consensus provides cover for analysts' reputations. We question the ethics of this practice when the motive to protect one's reputation takes precedence over the forecast accuracy motive. While seemingly predictable behavior from a self interested perspective, herding behavior has subtle but long term ramifications for the efficient pricing of securities and the preservation of the public trust in the financial services profession. We call upon each individual analyst as well as the profession to exercise the moral courage necessary to cultivate a climate of personal and public integrity. Personal resistance and pro-active policies are prescribed as actions to assist analysts to become more cognizant of their motivations, as well as to promote a more ethical professional context.     

The Relationship between Processing Styles and Self-Control Behavioral Characteristics

Recent research suggests that cognitions and affect may operate independently or simultaneously during the decision process. The purpose of this exploratory research is to understand cognitive and affective processing styles by examining the self-control traits which may be associated with each style. Results suggest that individuals prone to affective decision processing (Feeling Processors) also tended towards more compulsive behavior than the other types of processors. Similarly, individuals who use both styles of processing (Combination Processors) were found to be more likely to engage in risk-taking behavior. Implications of these results and future research are suggested.     

Business Ethics: A European Review: Change and Continuity

As was announced at the beginning of this volume of Business Ethics: A European Review , the current editor is retiring from the editorship at the end of this year. It gives him great pleasure to announce that he will be succeeded as Editor of the Review by Dr Jane Collier, of the Judge Institute, Cambridge. In this invited article Dr Collier offers some reflections on how she envisages the future of the Review.     

Smith and Living Wages: Arguments in Support of a Mandated Living Wage

Adam Smith was a proponent of living wages for labor for reasons of growth and for reasons of equity. There is ample evidence in the body of Smith's work to support the thesis that Smith would support public policies that might ensure the achievement of a living wage. The argument rests, in part, on the conclusion that Smith had reservations concerning the ability of the economy to experience sufficient growth and the ability of growth, if achieved, to secure living wages. This article argues that, given Smith's views about justice and given Smith's ideas, as part of the Scottish Enlightenment, of how the rules of justice evolve, a living wage law could be one of the general rules of which Smith could approve.     

The contribution of increased life expectancy to economic development in twentieth century Japan

This paper estimates the value of improved health in Japan over the twentieth century. By valuing the decline in the death rate and appending this to existing measures of GDP per capita it is possible to calculate health augmented GDP per capita growth and generate original results about the monetary value of improved life expectancy over the twentieth century in Japan. The findings of the paper indicate that this is a pertinent exercise because GDP per capita growth approximately doubles when it is extended to include increases in the life expectancy of the population of Japan. These results also provide a justification for the increase in health care service spending that was evident at the close of the twentieth century.     

Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study

Objective: To evaluate medical resource utilization (MRU) and associated costs among Australian patients with genotype 1 chronic hepatitis C (GT1 CHC), including both untreated patients and those receiving treatment with first-generation protease inhibitor-based regimens (telaprevir, boceprevir with pegylated interferon and ribavirin).

Methods: Medical records were reviewed for a stratified random sample of GT1 CHC patients first attending two liver clinics between 2011–2013 (principal population; PP), supplemented by all GT1 CHC patients attending one transplant clinic in the same period (transplant population; TP). CHC-related MRU and associated costs are reported for the PP by treatment status (treated/not treated) stratified by baseline fibrosis grade; and for the TP for the pre-transplant, year of transplant and post-transplant periods.

Results: A total 1636 patients were screened and 590 patients (36.1%) were included. Comprehensive MRU data were collected for 276 PP patients (F0–1 n?=?59, F2 n?=?58, F3 n?=?53, F4 n?=?106; mean follow-up?=?17.3 months). Thirty-eight (13.8%) were treatment-experienced prior to enrolment; 55 (19.9%) received triple therapy during the study. Data were collected for 112 TP patients (mean follow-up?=?29.9 months), 33 (29.5%) received a transplant during the study, and 51 (45.5%) beforehand. The annual direct medical costs, excluding drug costs, were higher among treated PP vs untreated PP (AU$: $1,954 vs $1,202); and year of transplant TP vs pre-/post-transplant TP (AU$: pre-transplant $32,407, transplant $155,138, post-transplant $7,358).

Limitations: To aid interpretation of results, note that only patients with GT1 CHC who are actively managed are included, and MRU data were collected specifically from liver outpatient clinics. That said, movement of patients between hospitals is rare, and any uncaptured MRU is expected to be minimal.

Conclusions: CHC-related MRU increases substantially with disease severity. These real-world MRU data for GT1 CHC will be valuable in assessing the impact of new hepatitis C treatments.